Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance

Abeona Therapeutics IncTrade
Direxion Daily S&P 500 Bull 3X SharesTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Direxion Daily S&P 500 Bull 3X Shares trades at $295.2. Which is the better fit depends on your goals.

ABEOSPXL
Market Cap
$421.19M
Sector
HealthLeveraged / Inverse
52-Week High
$7.45$296.39
52-Week Low
$4.17$170.20
Enterprise Value
$276.10M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.

Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.

Direxion Daily S&P 500 Bull 3X Shares

SPXL trades at $295.39, down 0.27% in the last session, with technical indicators showing a bullish trend from moving averages but overbought signals from RSI levels above 70. The stock's pivot point at $294 and resistance at $296 suggest near-term price sensitivity. Recent news highlights S&P 500 record highs and AI-driven earnings optimism, though valuation concerns persist.

Outlook remains cautiously optimistic amid strong market momentum, with opportunities from AI growth and corporate earnings, but risks include high valuations and potential pullbacks. Investors should balance bullish technicals with fundamental prudence.

Returns comparison

Trailing returns across standard periods

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Direxion Daily S&P 500 Bull 3X Shares

SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.

Read more on SPXL